Pharmos Completes Preclinical Toxicology And Safety Pharmacology Studies In Oral Cannabinor

... Pharmos Corp. (Nasdaq: PARS) today announced the completion of preclinical toxicology and safety pharmacology studies of an oral formulation of cannabinor, a synthetic CB2-selective agonist, to support dosing in humans. The toxicology studies included maximum tolerated dose (MTD) studies, a 28-day repeat-dose study, and a cardiovascular safety study in animals. [click link for full article] ...